Cognition Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview

Cognition Therapeutics

22/03/2024 12:58

* Cognition Therapeutics Inc  CGTX.OQ   CGTX.O  is expected
to show no change in quarterly revenue when it reports 
results on March 26 for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Cognition Therapeutics
Inc is
for a loss of 34 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cognition
Therapeutics Inc is $5.50​, above​ its last closing price
of $1.89. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.20       -0.24      -0.22     Beat    6.9
 Jun. 30 2023  -0.15       -0.19      -0.16     Beat    15.3
 Mar. 31 2023  -0.18       -0.18      -0.21     Missed  -19.8​
 Dec. 31 2022  -0.05       -0.22      -0.20     Beat    10.9
 ​​Sep.        -0.34       -0.38      -0.29     Beat    24.5
 30 2022                                                
 Jun. 30 2022  -0.29       -0.32      -0.25     Beat    22.2​
 Mar. 31 2022  -0.29       -0.29      -0.17     Beat    40.7
 Dec. 31 2021  -0.17       -0.26      -11.74    Missed  -4,424
                                                        .1
 This summary was machine generated March 22 at 12:58 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)